Recommended Citation
Smith J, Ezekwe N, Pourang A, and Hamzavi I. Multifocal Myositis and Elevated CPK associated with the use of Ustekinumab for Hidradenitis Suppurativa. Br J Dermatol 2020.
Document Type
Article
Publication Date
12-28-2020
Publication Title
The British journal of dermatology
Abstract
ustekinumab (UST) is a human interleukin (IL)-12/IL-23 monoclonal antibody that has been approved by the Food and Drug Administration (FDA) to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. Off-label use of UST has shown promising results for hidradenitis suppurativa (HS) in patients that have failed therapy with adalimumab, the only FDA approved treatment for HS.
PubMed ID
33370450
ePublication
ePub ahead of print
COinS
